Sanjay Ahuja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sanjay Ahuja has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Michael A. Suster
Department of Electrical, Computer, and Systems Engineering, Case Western Reserve University, Cleveland, OH, USA
5 shared publications - Pedram Mohseni
Department of Electrical, Computer, and Systems Engineering, Case Western Reserve University, Cleveland, OH, USA
4 shared publications - Anirban Sen Gupta
Case Western Reserve University
3 shared publications - Dante Disharoon
Department of Biomedical Engineering Case Western Reserve University Cleveland OH USA
2 shared publications - Debnath Maji
Case Western Reserve University, Cleveland, OH
2 shared publications - Divyaswathi Citla-Sridhar
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (6)
Denecimig (Mim8) prophylaxis over 52 weeks in adolescents and adults with hemophilia A: FRONTIER2 extension study
- 28 August 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (6)
Open AccessDenecimig (Mim8) prophylaxis over 52 weeks in adolescents and adults with hemophilia A: FRONTIER2 extension study
- Open Access
- 9 January 2024
- Published by Wiley in European Journal of Haematology
- Vol. 112 (5) , 756-764
A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A
Introduction: The safety and efficacy of the extended half‐life factor VIII (FVIII) product damoctocog alfa pegol (BAY 94‐9027, Jivi®) has been demonstrated in the PROTECT VIII Kids study (NCT01775618), where male previously‐treated patients (PTPs) aged <12 years old with severe haemophilia A and ≥ 50 exposure days (EDs) were treated prophylactically. The PROTECT VIII Kids extension study assessed the long‐term safety and efficacy of damoctocog alfa pegol in the same population. Aim: To evaluate the long‐term impact of damoctocog alfa pegol in a post hoc subgroup analysis of adolescent patients in the PROTECT VIII Kids study and its extension from 12th birthday onwards. Methods: The current analysis included PTPs aged ≥12 years old, who remained in the extension for ≥6 months following their 12th birthday. The observation period was defined as the time from 12th birthday to the end of the extension period; all data from this birthday were included whether in the main study or extension phase. The main efficacy variable was annualised bleeding rate (ABR) and the main safety variable was the frequency of inhibitor development. Results: This subgroup analysis comprised 25 patients. Median observation time after 12th birthday was 3.2 years. Median total/joint/spontaneous ABRs in the observation period were 1.7/0.7/0.3, respectively. Safety findings were consistent with those reported for the overall study population; no confirmed FVIII inhibitors or anti‐drug antibodies were reported. Conclusions: Damoctocog alfa pegol is efficacious with a favourable safety profile in adolescents with haemophilia A, supporting its long‐term use in children and adolescents.
- 9 January 2024
- Published by Wiley in European Journal of Haematology
- Vol. 112 (5) , 756-764
Open AccessA post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A
Introduction: The safety and efficacy of the extended half‐life factor VIII (FVIII) product damoctocog alfa pegol (BAY 94‐9027, Jivi®) has been demonstrated in the PROTECT VIII Kids study (NCT01775618), where male previously‐treated patients (PTPs) aged <12 years old with severe haemophilia A and ≥ 50 exposure days (EDs) were treated prophylactically. The PROTECT VIII Kids extension study assessed the long‐term safety and efficacy of damoctocog alfa pegol in the same population. Aim: To evaluate the long‐term impact of damoctocog alfa pegol in a post hoc subgroup analysis of adolescent patients in the PROTECT VIII Kids study and its extension from 12th birthday onwards. Methods: The current analysis included PTPs aged ≥12 years old, who remained in the extension for ≥6 months following their 12th birthday. The observation period was defined as the time from 12th birthday to the end of the extension period; all data from this birthday were included whether in the main study or extension phase. The main efficacy variable was annualised bleeding rate (ABR) and the main safety variable was the frequency of inhibitor development. Results: This subgroup analysis comprised 25 patients. Median observation time after 12th birthday was 3.2 years. Median total/joint/spontaneous ABRs in the observation period were 1.7/0.7/0.3, respectively. Safety findings were consistent with those reported for the overall study population; no confirmed FVIII inhibitors or anti‐drug antibodies were reported. Conclusions: Damoctocog alfa pegol is efficacious with a favourable safety profile in adolescents with haemophilia A, supporting its long‐term use in children and adolescents.
- Open Access
- 11 November 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7, 100389
OC 15.5 Detection of TIC-Relevant Phenotypes using Bioactive Reagent-Functionalized Dielectric Coagulometry Microsensors
- 11 November 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7, 100389
Open AccessOC 15.5 Detection of TIC-Relevant Phenotypes using Bioactive Reagent-Functionalized Dielectric Coagulometry Microsensors
- 3 July 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Circuits and Systems
- Vol. 17 (4) , 843-856
A Multichannel Portable Platform With Embedded Thermal Management for Miniaturized Dielectric Blood Coagulometry
This paper presents a standalone, multichannel, miniaturized impedance analyzer (MIA) system for dielectric blood coagulometry measurements with a microfluidic sensor termed ClotChip. The system incorporates a front-end interface board for 4-channel impedance measurements at an excitation frequency of 1 MHz, an integrated resistive heater formed by a pair of printed-circuit board (PCB) traces to keep the blood sample near a physiologic temperature of 37°C, a software-defined instrument module for signal generation and data acquisition, and a Raspberry Pi-based embedded computer with 7-inch touchscreen display for signal processing and user interface. When measuring fixed test impedances across all four channels, the MIA system exhibits an excellent agreement with a benchtop impedance analyzer, with rms errors of ≤0.30% over a capacitance range of 47–330 pF and ≤0.35% over a conductance range of 2.13–10 mS. Using in vitro -modified human whole blood samples, the two ClotChip output parameters, namely, the time to reach a permittivity peak ( Tpeak ) and maximum change in permittivity after the peak (Δϵ r,max ) are assessed by the MIA system and benchmarked against the corresponding parameters of a rotational thromboelastometry (ROTEM) assay. Tpeak exhibits a very strong positive correlation (r = 0.98, p < 10 -6 , n = 20) with the ROTEM clotting time ( CT ) parameter, while Δϵ r,max exhibits a very strong positive correlation (r = 0.92, p < 10 -6 , n = 20) with the ROTEM maximum clot firmness ( MCF ) parameter. This work shows the potential of the MIA system as a standalone, multichannel, portable platform for comprehensive assessment of hemostasis at the point-of-care/point-of-injury (POC/POI).
- 3 July 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Circuits and Systems
- Vol. 17 (4) , 843-856
A Multichannel Portable Platform With Embedded Thermal Management for Miniaturized Dielectric Blood Coagulometry
This paper presents a standalone, multichannel, miniaturized impedance analyzer (MIA) system for dielectric blood coagulometry measurements with a microfluidic sensor termed ClotChip. The system incorporates a front-end interface board for 4-channel impedance measurements at an excitation frequency of 1 MHz, an integrated resistive heater formed by a pair of printed-circuit board (PCB) traces to keep the blood sample near a physiologic temperature of 37°C, a software-defined instrument module for signal generation and data acquisition, and a Raspberry Pi-based embedded computer with 7-inch touchscreen display for signal processing and user interface. When measuring fixed test impedances across all four channels, the MIA system exhibits an excellent agreement with a benchtop impedance analyzer, with rms errors of ≤0.30% over a capacitance range of 47–330 pF and ≤0.35% over a conductance range of 2.13–10 mS. Using in vitro -modified human whole blood samples, the two ClotChip output parameters, namely, the time to reach a permittivity peak ( Tpeak ) and maximum change in permittivity after the peak (Δϵ r,max ) are assessed by the MIA system and benchmarked against the corresponding parameters of a rotational thromboelastometry (ROTEM) assay. Tpeak exhibits a very strong positive correlation (r = 0.98, p < 10 -6 , n = 20) with the ROTEM clotting time ( CT ) parameter, while Δϵ r,max exhibits a very strong positive correlation (r = 0.92, p < 10 -6 , n = 20) with the ROTEM maximum clot firmness ( MCF ) parameter. This work shows the potential of the MIA system as a standalone, multichannel, portable platform for comprehensive assessment of hemostasis at the point-of-care/point-of-injury (POC/POI).
- 26 April 2022
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 210, 114299
Assessment of fibrinolytic status in whole blood using a dielectric coagulometry microsensor
- 26 April 2022
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 210, 114299
Assessment of fibrinolytic status in whole blood using a dielectric coagulometry microsensor
- Open Access
- 22 April 2022
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 6 (3) , e12708
Thrombotic microangiopathies: An illustrated review
- 22 April 2022
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 6 (3) , e12708
Open AccessThrombotic microangiopathies: An illustrated review
- Open Access
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (Supplement) , 40-41
BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study
IntroductionBAY 94-9027 (damoctocog alfa pegol) is an extended-half-life PEGylated recombinant factor VIII approved for use in patients with hemophilia A aged ≥
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (Supplement) , 40-41
Open AccessBAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study
IntroductionBAY 94-9027 (damoctocog alfa pegol) is an extended-half-life PEGylated recombinant factor VIII approved for use in patients with hemophilia A aged ≥
- Open Access
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 4662
Assessment of Bleeding Phenotype in Hemophilia Α By a Novel Point-of-Care Global Assay
Introduction: Patients with Hemophilia A have considerable phenotypic heterogeneity with respect to clinical severity based on their baseline factor levels. As clinical bleeding risk is helpful to individualize factor replacement therapy in hemophilia patients, previous studies have utilized direct and indirect methods of thrombin generation to classify individual bleeding phenotypes, however, with variable results. An easy to use, point-of-care, global assay to assess bleed phenotype, can be a useful tool in the clinical setting to determine intensity of prophylaxis therapy for patients with hemophilia. We have previously introduced a novel, point-of-care (POC), dielectric microsensor, ClotChip, and demonstrated its sensitivity to factor replacement in patients with severe hemophilia A. We aim to further test the ability of ClotChip in assessment of a bleeding phenotype, as described by a bleeding score, in patients with hemophilia A. Methods: After IRB approval, 28 patients with hemophilia A of varying severity and well-characterized bleeding history, were enrolled in this study at the time of trough factor levels. The bleeding history was extracted from patient charts and included number of bleeds (joint and soft-tissue), annual factor usage in terms of units/kg, and number of target joints. These parameters were used to generate a bleeding score (range: 0 - 24), and patients were divided in to 2 categories with scores between 0 - 12 (n=14) and > 12 (n=14). Healthy volunteers (n=17) were accrued as controls. Whole blood samples were obtained by venipuncture into collection tubes containing 3.2% sodium citrate. Samples were then tested with the ClotChip within 2 hours of collection. ClotChip is based on the electrical technique of dielectric spectroscopy (DS) and features a low-cost (material cost < $1), small- sized (26mm × 9mm × 3mm), and disposable microfluidic biochip with miniscule sample volume (< 10 µL). The ClotChip readout was taken as the temporal variation in the real part of blood dielectric permittivity at 1 MHz. Our previous studies have shown that the ClotChip readout is sensitive to the global coagulation process and the time to reach a peak in permittivity (Tpeak) is a sensitive parameter to assess coagulation factor defects. Thrombin generation assay (TGA) using low tissue factor concentration was also performed on blood samples according to the manufacturer's direction. TGA was not available for 4 hemophilia and 2 control samples. Endogenous thrombin potential (ETP) parameter of TGA was used in this study to assess thrombin generation. Data are reported as mean ± standard deviation (SD). Analysis of variance (ANOVA) was used to test for statistical significance between groups with P < 0.05. Spearman's correlation test was used to derive correlation statistics. Results: ClotChip exhibited a mean Tpeak of 2186s ± 1560s for hemophilia patients in the group with higher bleeding scores (i.e. score >12), a mean Tpeak of 931s ± 496s for the group with lower bleeding scores (i.e. score peak of 441s ± 74s for the healthy group (Figure 1A). A significant difference in Tpeak was found between the group with higher bleeding scores compared to the group with lower bleeding scores (P = 0.002) as well as between higher bleeding scores and the healthy group (P < 0.0001). However, no significant difference in the TGA ETP parameter was detected between the groups with higher bleeding scores (mean ETP: 470 ± 814) and lower bleeding scores (mean ETP: 471 ± 897) (Figure 1B). ETP exhibited a statistical difference between the healthy group (mean ETP: 3462 ± 575) and both hemophilia groups (P < 0.0001). We also carried out studies to investigate the correlative power of the ClotChip Tpeak parameter to the TGA ETP parameter when including additional blood samples that were collected at various times during a hemophilia patient's prophylaxis regimen. The ClotChip Tpeak parameter exhibited strong negative correlation to the TGA ETP parameter (Spearman's rs= -0.73, P < 0.0001). Conclusions: Our studies suggest that a novel dielectric microsensor (ClotChip) could be useful in assessing bleeding phenotype in hemophilia A patients, allowing rapid assessment of hemostasis using a miniscule amount of whole blood (<10 µL) at the POC. Further studies are needed to determine if ClotChip data can be used to individualize prophylactic factor replacement regimens in hemophilia A patients.
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 4662
Open AccessAssessment of Bleeding Phenotype in Hemophilia Α By a Novel Point-of-Care Global Assay
Introduction: Patients with Hemophilia A have considerable phenotypic heterogeneity with respect to clinical severity based on their baseline factor levels. As clinical bleeding risk is helpful to individualize factor replacement therapy in hemophilia patients, previous studies have utilized direct and indirect methods of thrombin generation to classify individual bleeding phenotypes, however, with variable results. An easy to use, point-of-care, global assay to assess bleed phenotype, can be a useful tool in the clinical setting to determine intensity of prophylaxis therapy for patients with hemophilia. We have previously introduced a novel, point-of-care (POC), dielectric microsensor, ClotChip, and demonstrated its sensitivity to factor replacement in patients with severe hemophilia A. We aim to further test the ability of ClotChip in assessment of a bleeding phenotype, as described by a bleeding score, in patients with hemophilia A. Methods: After IRB approval, 28 patients with hemophilia A of varying severity and well-characterized bleeding history, were enrolled in this study at the time of trough factor levels. The bleeding history was extracted from patient charts and included number of bleeds (joint and soft-tissue), annual factor usage in terms of units/kg, and number of target joints. These parameters were used to generate a bleeding score (range: 0 - 24), and patients were divided in to 2 categories with scores between 0 - 12 (n=14) and > 12 (n=14). Healthy volunteers (n=17) were accrued as controls. Whole blood samples were obtained by venipuncture into collection tubes containing 3.2% sodium citrate. Samples were then tested with the ClotChip within 2 hours of collection. ClotChip is based on the electrical technique of dielectric spectroscopy (DS) and features a low-cost (material cost < $1), small- sized (26mm × 9mm × 3mm), and disposable microfluidic biochip with miniscule sample volume (< 10 µL). The ClotChip readout was taken as the temporal variation in the real part of blood dielectric permittivity at 1 MHz. Our previous studies have shown that the ClotChip readout is sensitive to the global coagulation process and the time to reach a peak in permittivity (Tpeak) is a sensitive parameter to assess coagulation factor defects. Thrombin generation assay (TGA) using low tissue factor concentration was also performed on blood samples according to the manufacturer's direction. TGA was not available for 4 hemophilia and 2 control samples. Endogenous thrombin potential (ETP) parameter of TGA was used in this study to assess thrombin generation. Data are reported as mean ± standard deviation (SD). Analysis of variance (ANOVA) was used to test for statistical significance between groups with P < 0.05. Spearman's correlation test was used to derive correlation statistics. Results: ClotChip exhibited a mean Tpeak of 2186s ± 1560s for hemophilia patients in the group with higher bleeding scores (i.e. score >12), a mean Tpeak of 931s ± 496s for the group with lower bleeding scores (i.e. score peak of 441s ± 74s for the healthy group (Figure 1A). A significant difference in Tpeak was found between the group with higher bleeding scores compared to the group with lower bleeding scores (P = 0.002) as well as between higher bleeding scores and the healthy group (P < 0.0001). However, no significant difference in the TGA ETP parameter was detected between the groups with higher bleeding scores (mean ETP: 470 ± 814) and lower bleeding scores (mean ETP: 471 ± 897) (Figure 1B). ETP exhibited a statistical difference between the healthy group (mean ETP: 3462 ± 575) and both hemophilia groups (P < 0.0001). We also carried out studies to investigate the correlative power of the ClotChip Tpeak parameter to the TGA ETP parameter when including additional blood samples that were collected at various times during a hemophilia patient's prophylaxis regimen. The ClotChip Tpeak parameter exhibited strong negative correlation to the TGA ETP parameter (Spearman's rs= -0.73, P < 0.0001). Conclusions: Our studies suggest that a novel dielectric microsensor (ClotChip) could be useful in assessing bleeding phenotype in hemophilia A patients, allowing rapid assessment of hemostasis using a miniscule amount of whole blood (<10 µL) at the POC. Further studies are needed to determine if ClotChip data can be used to individualize prophylactic factor replacement regimens in hemophilia A patients.
- 7 July 2019
- Published by Wiley in Haemophilia
- Vol. 25 (5) , 885-892
A novel, point‐of‐care, whole‐blood assay utilizing dielectric spectroscopy is sensitive to coagulation factor replacement therapy in haemophilia A patients
Background Reliable monitoring of coagulation factor replacement therapy in patients with severe haemophilia, especially those with inhibitors, is an unmet clinical need. While useful, global assays, eg thromboelastography (TEG), rotational thromboelastometry (ROTEM) and thrombin generation assay (TGA), are cumbersome to use and not widely available. Objective To assess the utility of a novel, point‐of‐care, dielectric microsensor – ClotChip – to monitor coagulation factor replacement therapy in patients with haemophilia A, with and without inhibitors. Methods The ClotChip Tpeak parameter was assessed using whole‐blood samples from children with severe haemophilia A, with (n = 6) and without (n = 12) inhibitors, collected pre‐ and postcoagulation factor replacement therapy. ROTEM, TGA and chromogenic FVIII assays were also performed. Healthy children (n = 50) served as controls. Results ClotChip Tpeak values exhibited a significant decrease for samples collected postcoagulation factor replacement therapy as compared to baseline (pretherapy) samples in patients with and without inhibitors. A difference in Tpeak values was also noted at baseline among severe haemophilia A patients with inhibitors as compared to those without inhibitors. ClotChip Tpeak parameter exhibited a very strong correlation with clotting time (CT) of ROTEM, endogenous thrombin potential (ETP) and peak thrombin of TGA, and FVIII clotting activity. Conclusions ClotChip is sensitive to coagulation factor replacement therapy in patients with severe haemophilia A, with and without inhibitors. ClotChip Tpeak values correlate very well with ROTEM, TGA and FVIII assays, opening up possibilities for its use in personalized coagulation factor replacement therapy in haemophilia.
- 7 July 2019
- Published by Wiley in Haemophilia
- Vol. 25 (5) , 885-892
A novel, point‐of‐care, whole‐blood assay utilizing dielectric spectroscopy is sensitive to coagulation factor replacement therapy in haemophilia A patients
Background Reliable monitoring of coagulation factor replacement therapy in patients with severe haemophilia, especially those with inhibitors, is an unmet clinical need. While useful, global assays, eg thromboelastography (TEG), rotational thromboelastometry (ROTEM) and thrombin generation assay (TGA), are cumbersome to use and not widely available. Objective To assess the utility of a novel, point‐of‐care, dielectric microsensor – ClotChip – to monitor coagulation factor replacement therapy in patients with haemophilia A, with and without inhibitors. Methods The ClotChip Tpeak parameter was assessed using whole‐blood samples from children with severe haemophilia A, with (n = 6) and without (n = 12) inhibitors, collected pre‐ and postcoagulation factor replacement therapy. ROTEM, TGA and chromogenic FVIII assays were also performed. Healthy children (n = 50) served as controls. Results ClotChip Tpeak values exhibited a significant decrease for samples collected postcoagulation factor replacement therapy as compared to baseline (pretherapy) samples in patients with and without inhibitors. A difference in Tpeak values was also noted at baseline among severe haemophilia A patients with inhibitors as compared to those without inhibitors. ClotChip Tpeak parameter exhibited a very strong correlation with clotting time (CT) of ROTEM, endogenous thrombin potential (ETP) and peak thrombin of TGA, and FVIII clotting activity. Conclusions ClotChip is sensitive to coagulation factor replacement therapy in patients with severe haemophilia A, with and without inhibitors. ClotChip Tpeak values correlate very well with ROTEM, TGA and FVIII assays, opening up possibilities for its use in personalized coagulation factor replacement therapy in haemophilia.